SCHEMBL4074349

SCHEMBL4074349

Cc1ccc(S(=O)(=O)N2C(=O)CC[C@H]2C(=O)Cl)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
RAB9A P51151 1/20 0.57
POLB P06746 1/20 0.54
HTT P42858 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPK1 P28482 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MMP2 P08253 5/20 0.52
MMP9 P14780 1/20 0.52
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
ALDH1A1 P00352 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ANPEP P15144 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5082404 0.87 MEN1 (0.61) KMT2AMEN1RAB9APOLBHTT
SCHEMBL4015124 0.87 MEN1 (0.61) KMT2AMEN1RAB9APOLBHTT
SCHEMBL13845797 0.77 POLB (0.52) KMT2AMEN1RAB9APOLBHTT
SCHEMBL13845795 0.76 MEN1 (0.55) KMT2AMEN1RAB9APOLBHTT
SCHEMBL13849822 0.75 POLB (0.48) KMT2AMEN1RAB9APOLBHTT
SCHEMBL13845793 0.75 POLB (0.55) KMT2AMEN1RAB9APOLBHTT
SCHEMBL16600839 0.75 MEN1 (0.49) KMT2AMEN1RAB9APOLBHTT
SCHEMBL4674925 0.74 GAA (0.63) KMT2AMEN1POLBKDM4EMAPK1
SCHEMBL4077463 0.74 GAA (0.63) KMT2AMEN1POLBKDM4EMAPK1
SCHEMBL25243550 0.74 MEN1 (0.71) KMT2AMEN1RAB9APOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538245-B2 Process for the manufacture of an enantiopure compound SOLVAY S.A. (BE) 2009-05-26 US disclosed
US-20080027211-A1 Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments SOLVAY S.A. (BE) 2008-01-31 US disclosed
US-20070027326-A1 Process for the manufacture of an enantiopure compound SOLVAY S.A. (BE) 2007-02-01 US disclosed
EP-1664084-A1 PROCESS FOR THE MANUFACTURE OF AN ENANTIOPURE COMPOUND SOLVAY (Société Anonyme) (BE) 2006-06-07 EP disclosed
WO-2005023838-A1 PROCESS FOR THE MANUFACTURE OF AN ENANTIOPURE COMPOUND Solvay (Société Anonyme) (BE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027211-A1 Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments NPR3, VIP, NPPA KMT2A 4324/4885MEN1 206/4885RAB9A 3526/4885
US-20070027326-A1 Process for the manufacture of an enantiopure compound AMD1, DAO, DDC KMT2A 3516/4885MEN1 3808/4885RAB9A 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.